Business Wire

ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions of HIV with ‘HIV in View’ - a first-of-its-kind online HIV photography gallery

Share

ViiV Healthcare and Shutterstock Studios today announced the launch of a new online photo gallery ‘HIV in View’, produced by Shutterstock in collaboration with ViiV Healthcare. The collection, curated with the support of people living with HIV, leverages Shutterstock’s global network of over one million creators to deliver a repository of high-resolution images depicting what it means to live with HIV today. Across four countries (the United Kingdom, Kenya, Uruguay, Portugal), people living with HIV stepped forward to be among the first photographed for this gallery, embarking on a shared ambition to help shift the world’s perception of HIV and move away from outdated stereotypes. From World AIDS Day 2020, the gallery will be free for all to access and use in projects, campaigns and communications* in the hope that it will increase awareness around HIV and break down barriers to stigma that still exist.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201201005521/en/

ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions of HIV with ‘HIV in View’ - a first-of-its-kind online HIV photography gallery (Photo: Business Wire)

ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions of HIV with ‘HIV in View’ - a first-of-its-kind online HIV photography gallery (Photo: Business Wire)

Doreen Moracha, aged 28, from Nairobi, Kenya, one of the first people to be photographed for the gallery and HIV Advocate, said, “I am so proud to be one of the first people to be photographed for the ‘HIV in View’ gallery and to be part of a movement for change to represent real people living with HIV, their stories and experiences. Until the world sees HIV for what it really is, we are not going to make the progress we need to disrupt stereotypes of what it’s like to live with HIV. If my photographs can change just one person’s opinion of what it means to live with HIV today, I will know we are a step closer to reaching this goal.”

Today, living with HIV is a very different experience from just ten years ago. Advances in prevention, treatment and care mean that people living with HIV can live longer, healthier lives, with a person starting treatment at 20 years old now able to expect to see their 77th birthday.1 Despite these advances, people living with HIV face unique challenges that affect their quality of life every day. Stigma remains a stubbornly persistent threat to the health and well-being of many people living with HIV, and can often impact their ability to consistently access life-saving treatments and social support systems.2 In the battle to challenge the negative assumptions about HIV, shining a light on the truth can be a potent strategy. Sharing the true picture and experiences of people living with HIV is key to undermining stigma.

Deborah Waterhouse, CEO, ViiV Healthcare, said, “At ViiV Healthcare, our mission is to leave no person living with HIV behind and reducing HIV-related stigma is key to achieving this. For too long, the public has been presented with outdated representations of what it is to live with HIV. Working with Shutterstock has underlined how a lack of widely accessible, present-day HIV imagery continues to hold us back. With the launch of the ‘HIV in View’ gallery, people across the world can now download authentic photography for free. As a company, we are making a pledge to use images of real people living with HIV across all our platforms, where applicable, moving forward and we encourage others to do the same. Living with HIV has changed, and we invite the world to help us show this.”

Michael Carfagnini, GM Global Shutterstock Studios, said, “ViiV Healthcare’s work in continuing to fight HIV-related stigma until people living with HIV are understood and accepted sparked a unique opportunity for Shutterstock to collaborate through powerful visuals. There is always a need for authentic and fresh imagery accurately depicting what it's like to live with HIV. At Shutterstock, we strive to empower the world’s storytellers through our content and services such as those offered through our new Studios division enabling brands and agencies to tell their unique stories. This presented an opportunity to prove the effectiveness and adaptability of our global network of contributors who would be tasked with safely depicting this crucial story, in a much more challenging time to do photography and videography with a pandemic limiting production around the world. This project and the various teams involved both at Shutterstock and ViiV Healthcare truly demonstrated the impact passion brings to creative projects, and we saw the same quality from our contributors and people living with HIV featured in the imagery.”

The ‘HIV in View’ gallery is produced by Shutterstock and created in collaboration with ViiV Healthcare. All images can be downloaded royalty free here: https://www.shutterstock.com/explore/viiv-collaboration.

Notes to editor

*The HIV in View collection will be offered for free under Shutterstock’s standard license to use in projects, campaigns and communications. Users who require the enhanced license will be charged the higher license fee, of which 100% of the proceeds will be donated to (RED), a non-profit organisation helping fund the fight to end AIDS, at the discretion of Shutterstock. For additional information on the license comparison, visit: https://www.shutterstock.com/license-comparison.

About Shutterstock, Inc.

Shutterstock, Inc. (NYSE: SSTK), directly and through its group subsidiaries, is a leading global provider of high-quality licensed photographs, vectors, illustrations, videos and music to businesses, marketing agencies and media organizations around the world. Working with its growing community of over 1 million contributors, Shutterstock adds hundreds of thousands of images each week, and currently has more than 350 million images and more than 20 million video clips available.

Headquartered in New York City, Shutterstock has offices around the world and customers in more than 150 countries. The company’s brands also include Bigstock, a value-oriented stock media offering; Shutterstock Custom, a custom content creation platform; Offset, a high-end image collection; PremiumBeat, a curated royalty-free music library; and Shutterstock Editorial, a premier source of editorial images and videos for the world's media.

For more information, please visit www.shutterstock.com and follow Shutterstock on Twitter and on Facebook.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company’s aims are to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and as set out in GSK’s “Principal risks and uncertainties” section of the Q3 Results and any impacts of the COVID-19 pandemic.

Registered in England & Wales:
No. 3888792

Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS

1. May et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. Available at: https://pubmed.ncbi.nlm.nih.gov/24556869/ Last accessed: December 2020.

2. Avert. HIV stigma and discrimination. Available at: https://www.avert.org/professionals/hiv-social-issues/stigma-discrimination Last accessed: December 2020.

Contact information

Shutterstock media enquiries – corporate or people living with HIV interviews:
Lara Baez, Communications Associate
press@shutterstock.com

ViiV Healthcare media enquiries – corporate only interviews:

Kate Senter, Global Corporate and Internal Communications Director
kate.x.senter@viivhealthcare.com

Daria Sadchikova, Communications and Government Affairs Associate
daria.x.sadchikova@viivhealthcare.com

GSK media enquiries – corporate only interviews:
Simon Steel (London) - +44 (0) 20 8047 5502
Tim Foley (London) - +44 (0) 20 8047 5502
Kristen Neese (Philadelphia) - +1 804 217 8147
Kathleen Quinn (Washington DC) - +1 202 603 5003

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Argo Blockchain PLC announces £22.4 Million Private Placement with Institutional Investors and Mining Capacity Expansion18.1.2021 11:46:00 EETPress release

Argo, the leading cryptocurrency miner based in the UK (LSE:ARB), is pleased to announce that it has entered into a securities purchase agreement for a private placement of its ordinary shares ("Ordinary Shares") to certain institutional investors for gross proceeds of GBP £22.4 million (the "Private Placement"). Pursuant to the Private Placement, the Company will issue 28 million Ordinary Shares (the “Placement Shares”) at a purchase price of GBP £0.80 per Ordinary Share. The Private Placement is limited to those certain institutional investors that have already subscribed and this announcement should not be considered an offer or solicitation to purchase or subscribe for securities in the United States. H.C. Wainwright & Co. is acting as the exclusive placement agent for the Private Placement. The net proceeds of the Private Placement will be used by the Company for working capital and general corporate purposes, including the expansion of the Company’s mining capacity in Q1 and Q2 o

Reply Signs an Agreement with AWS to Develop Industry Solutions18.1.2021 11:30:00 EETPress release

Reply, specialized on new communications channels and digital media, announces today it has signed a Strategic Collaboration Agreement (SCA) with Amazon Web Services (AWS) to develop industry solutions for Financial Services, Manufacturing, Automotive, Retail, Energy, and Telco customers. Through this SCA, the Reply Group of companies dedicated to AWS – Comsysto Reply, Data Reply, Sense Reply, and Storm Reply – will work with organizations of virtually all sizes and allow them to innovate faster and deliver consistent improvements on their business processes using advanced and secure AWS technologies. Reply’s companies dedicated to AWS will offer solutions for highly regulated Financial Services customers, providing them with strategic advisory and security-related consultancy, practices, and frameworks to modernize legacy platforms and solutions designed to address fraud and financial-crime use cases. They will also provide Industrial and Manufacturing customers with the tools they ne

L&T Technology Services Rated as Global Pure-Play ER&D Services Leader by Zinnov18.1.2021 11:00:00 EETPress release

L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, today announced that it has been rated as a ‘Leader’ in new technologies critical for products and services transformation and also placed in the Leadership Zone across major ER&D Services’ sectors in the Zinnov Zones 2020 ER&D Services study for the fourth consecutive year. LTTS continued to hold the top leadership position in the pure play ER&D Services category in the Zinnov Zones assessments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005070/en/ LTTS rated as a Global Leader in ER&D Services in Zinnov Zones 2020. (Graphic: Zinnov) In its latest industry rankings, Zinnov positioned L&T Technology Services as an “Expansive and Established” engineering partner with deep domain competencies in overall ER&D services. LTTS has been rated in the “Leadership Zone” across verticals such as Automotive, Aeros

Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe18.1.2021 11:00:00 EETPress release

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, have agreed to enter into a partnership to establish in-house liquid biopsy testing services, using Guardant Health’s industry-leading proprietary digital sequencing platform, at VHIO’s facility in Barcelona, Spain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210118005057/en/ The service is expected to become operational in 2021 and will be available for clinical research and clinical care — starting with private patients, followed by expansion into the public healthcare system over time. “We are pleased to announce this partnership with VHIO which will bring liquid biopsy comprehensive genomic testing to more cancer patients in Spain and beyond,” said Helmy Eltoukhy, Guardant Health CEO. “Our vision is that all cancer patients globally have access

Topcon Announces eyeRISE 2021 Virtual Symposia & Expo18.1.2021 09:00:00 EETPress release

Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that it will host a two-day virtual symposia and expo entitled eyeRISE on February 9-10, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210117005025/en/ eyeRISE, or Eye Research Innovation Symposia & Expo, is a new, multi-disciplinary virtual congress showcasing the latest innovations in eye care. It will feature three solutions-focused tracks, delivering clinical and practical education through symposia, roundtable discussions and interactive workshops. (Graphic: Business Wire) eyeRISE, or Eye Research Innovation Symposia & Expo, is a new, multi-disciplinary virtual congress showcasing the latest innovations in eye care. It will feature three solutions-focused tracks, delivering clinical and practical education through symposia, roundtable discussions and interactive workshops. The two-day

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy17.1.2021 00:15:00 EETPress release

Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates. Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3 “For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are conti

H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 11:00:00 EETPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom